AP NEWS

Aimmune Therapeutics Announces CEO Jayson Dallas Will Present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15th

August 7, 2018

BRISBANE, Calif.--(BUSINESS WIRE)--Aug 7, 2018--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas, M.D., will give his first public presentation as the company’s President and CEO at the 2018 Wedbush PacGrow Healthcare Conference in New York on Wednesday, August 15 at 1:55 p.m. Eastern Time.

As Aimmune prepares to submit regulatory filings for marketing approval of AR101 in the United States and Europe, Dr. Dallas will provide a corporate overview and outline his vision for delivering on Aimmune’s commitment to serving those affected by food allergies. AR101 is Aimmune’s investigational biologic oral immunotherapy for desensitization of patients with peanut allergy.

Event: Wedbush PacGrow Healthcare Conference Presentation Date: August 15, 2018 Presentation Time: 1:55 p.m. Eastern Time Presenter: Jayson Dallas, M.D., President & CEO, Aimmune Therapeutics

A live webcast of the presentation will be accessible on the Events page under the Investor Relations section of the Aimmune Therapeutics website at www.aimmune.com. A replay of the webcast will be available for at least 30 days.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age. Aimmune plans to submit regulatory filings for marketing approval of AR101 in the United States and Europe based on data from the pivotal Phase 3 PALISADE clinical trial of AR101, which in 4-17 year-old subjects met all its primary and secondary endpoints, and additional ongoing and completed AR101 clinical trials. For more information, please see www.aimmune.com.

This press release concerns a product that is under clinical investigation and that has not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It is currently limited to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Aimmune’s expectations regarding its new chief executive officer; Aimmune’s expectations regarding the potential benefits of AR101; Aimmune’s expectations regarding potential applications of the CODIT™ approach to treating life-threatening food allergies; and Aimmune’s expectations regarding the timing of potential regulatory filings for marketing approval of AR101 in the United States and Europe. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the expectation that Aimmune will need additional funds to finance its operations; the company’s ability to initiate and/or complete clinical trials; the unpredictability of the regulatory process; the possibility that the results of early clinical trials may not be predictive of future results; the possibility that Aimmune’s clinical trials will not be successful; Aimmune’s dependence on the success of AR101; the company’s reliance on third parties for the manufacture of the company’s product candidates; possible regulatory developments in the United States and foreign countries; and Aimmune’s ability to attract and retain senior management personnel. These and other risks and uncertainties are described more fully in Aimmune’s most recent filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2018. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aimmune undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180807005289/en/

CONTACT: Aimmune Therapeutics, Inc.

Investors

Laura Hansen, Ph.D., 650-396-3814

lhansen@aimmune.com

or

Media

Stephanie Yao, 650-351-6479

syao@aimmune.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL

SOURCE: Aimmune Therapeutics, Inc.

Copyright Business Wire 2018.

PUB: 08/07/2018 08:00 AM/DISC: 08/07/2018 08:01 AM

http://www.businesswire.com/news/home/20180807005289/en

AP RADIO
Update hourly